ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Glycolytic Enzyme HK2 Phosphorylates nSMase1 to Promote Astrocytic Exosomes Biogenesis Contributing to Acute Ischemic Stroke Injury.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Galactokinase 1 Positively Regulates Mitochondrial Respiration by Phosphorylating TIMM13 as a Protein Kinase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Penumbra-derived small extracellular vesicles carry pathogenic RNA driving remote damage after cortical infarction.Brain : a journal of neurology · 2026Article
- Exosomal lncRNAs in Cerebrovascular Diseases: Biomarkers, Pathological Mechanisms, and Therapeutic Potential.Non-coding RNA · 2026Review
- Astrocytic SCAP deletion ameliorates diabetes-associated cognitive impairment by suppressing microglial neuroinflammation and lipid droplet accumulation via the LCN2-24p3R-mTOR axis.Cell death & disease · 2026Article
- Recent advances in research on novel therapeutic mechanisms and strategies for exosome-based treatment of ischemic stroke.Frontiers in pharmacology · 2026Review
- Glycolytic Enzyme HK2 Phosphorylates nSMase1 to Promote Astrocytic Exosomes Biogenesis Contributing to Acute Ischemic Stroke Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Stroke represents a significant threat to public health, with insufficient understanding of its pathological mechanisms hindering therapeutic advancements. Exosomes are implicated in both the injury and recovery processes of ischemic stroke. While enhanced glycolysis is linked to exosome biogenesis, its regulatory mechanisms remain largely unexplored. Here, an increase in the number of exosomes within the cerebrospinal fluid (CSF) and plasma in acute ischemic stroke is observed. Hypoxia selectively enhanced the exosomes biogenesis in astrocytes. Through RNAi screening, we identified the glycolytic enzyme hexokinase 2 (HK2) as a key promoter of hypoxia-induced exosomes. HK2 facilitates the formation of intraluminal vesicles (ILVs), the precursors of exosomes, without affecting their degradation in lysosomes. HK2 directly phosphorylates neutral sphingomyelinase 1 (nSMase1), a critical enzyme involved in the lipid biogenesis pathway of exosomes. Moreover, hypoxia-induced astrocytic exosomes disrupt cerebrovascular endothelial tight junction proteins. Astrocyte-specific knockdown of HK2 significantly reduces exosomes release and alleviates brain injury caused by middle cerebral artery occlusion (MCAO). Notably, MCAO markedly increased the phosphorylation of nSMase1, which is effectively abolished by astrocytic HK2 knockdown. In conclusion, this study reveals a non-metabolic role of HK2 in exosomes biogenesis via its protein kinase activity, offering a potential therapeutic target for stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.